Cyclerion Therapeutics, Inc. (CYCN)
| Market Cap | 86.20M |
| Revenue (ttm) | 3.54M |
| Net Income (ttm) | -60.10M |
| Shares Out | 43.32M |
| EPS (ttm) | -1.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,959 |
| Open | 2.00 |
| Previous Close | 1.96 |
| Day's Range | 1.90 - 2.04 |
| 52-Week Range | 1.62 - 6.90 |
| Beta | 1.71 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+427.6%) |
| Earnings Date | Nov 4, 2021 |
About CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cy...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CYCN stock is "Strong Buy" and the 12-month stock price forecast is 10.50.
News
Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive func...
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS)
Trending Penny Stocks to Buy Now? 5 to Watch This Week
Which trending penny stocks are on your watchlist right now? The post Trending Penny Stocks to Buy Now?
Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside
Truist analyst Joon Lee has initiated coverage of Cyclerion Therapeutics Inc (NASDAQ:CYCN) with a Buy rating and price target of $14, suggesting a massive 374% upside. The development of drugs targeting...
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant s...
Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cog...
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit
Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical assessm...
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive imp...
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Di...
Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics Research to be presented highlighting poten...
Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers
Cyclerion Therapeutics Inc (NASDAQ: CYCN) and Beacon Biosignals have expanded strategic partnerships between the two companies. This collaboration is expected to identify disease-relevant biomarkers to...
Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership
BOSTON, July 8, 2021 /PRNewswire/ -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies. This col...
Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases a...
Best Penny Stocks on Reddit to Buy? Check These 4 Out in June
Which penny stocks on Reddit are you watching? Here's 4 for some watchlist inspiration The post Best Penny Stocks on Reddit to Buy?
Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist
Meme penny stocks are heating up; are these 3 on your watchlist? The post Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informati...
Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise
Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the development and commercialization of praliciguat. Un...
Cyclerion Therapeutics Announces $18 Million Private Placement
Proceeds to fund ongoing clinical development of CY6463 and advancement of next generation CY3018 program Proceeds to fund ongoing clinical development of CY6463 and advancement of next generation CY301...
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator
Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthca...
Best Penny Stocks To Buy Right Now? 3 To Know Before Next Week
After this week's market pullback, some of these penny stocks are trending into the weekend. The post Best Penny Stocks To Buy Right Now?
Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) ...
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
Provided updates on development strategy and execution for CY6463, a first-in-class, CNS-penetrant sGC stimulator, including IND clearance from FDA in ADv and ongoing MELAS program
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
Senior CNS expert and biotech business leader to inform strategy and future clinical development Senior CNS expert and biotech business leader to inform strategy and future clinical development
Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week
5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...
Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive fun...
Cyclerion Therapeutics to Host Pipeline Update Webinar
Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS